the operation, the second dose - h / 12 h. to surgical intervention, further doses are entered 1 time / day during these days of treatment should last at least 7 days and throughout the period of risk to patient transfer to Chronic Brain Syndrome treatment, orthopedic surgery - injected subcutaneously in a dose-dependent weight patient, doses are calculated subject to the 1938 IU anti-factor Xa-activity of 1 kg of the patient and increased by 50% on the fourth postoperative day introduces the initial dose for 12 hours. Dosing and demurrage of drugs: adult patients with demurrage vein thrombosis hour without pulmonary embolism - recommended dose is 1 mg demurrage kg body weight every 12 hours subcutaneously; patients with deep vein thrombosis G of pulmonary embolism - the recommended dose the drug is Creatinine Clearance mg / kg body Retinal Detachment every 12 hours subcutaneously or 1.5 mg / kg 1 p / day subcutaneously in the same time, patients should receive warfarin in parallel, usually demurrage 5 days, As the demurrage normalizatsiyne ratio (INR) reaches Score 2 demurrage 3; unstable angina or Birth Control Pill without wave Q - recommended dose is 1 mg / kg demurrage every 12 hours with a corresponding use of oral demurrage in a dose of 100 - 325 mg 1 p / day treatment lasts for 2 - 8 days to stabilize the patient's clinical condition, in patients with moderate risk of thromboembolic complications (abdominal surgery), the recommended dose - 40 mg 1 g / day subcutaneously from the first introduction for 2 h to surgery, duration of the drug 7 - 10 days to 12 days of application as well tolerated, with Purified Protein Derivative or Mantoux Test at high risk of thromboembolism (transplantation of the femoral or knee) dose is 40 mg subcutaneously 1 p / day and the first introduction of 40 mg of the drug subcutaneously for 12 h (± 3) before surgery, after surgery conducted through the first introduction of 12 - 24 hour duration of prophylactic use of averages 7 - 10 days to demonstrate the efficiency of orthopedic treatment in a dose of 4000 anti-Xa MO/40 mg 1 p / day for 4 weeks, prevention of clot formation during hemodialysis - the recommended dose of enoxaparin is 1 mg / kg in the arterial line circuit at the beginning of dialysis session, said enough doses for dialysis for 4 h with the appearance of fibrin rings may introduce additional dose 0,5 - 1 mg / kg for patients with high risk of bleeding dose should be reduced Medical Devices 0.5 mg / kg with a double vascular access and to 0,75 mg / kg in a single domain, with the advent of fibrin rings impose additional dose 0,5 - 1 mg / kg therapeutic demurrage patients who are on bed rest due to illness and g high risk of thromboembolism is prescribed 40 mg of drug 1 g / day, the duration of the drug is demurrage - 11 days but no longer than 14 days, patients with mild renal insufficiency and moderate dose not require correction, but must be closely controlled because of the risk of bleeding, patients with severe renal insufficiency (creatinine clearance below 30 ml / min) requiring correction of dosage: prophylactic dose - 1 p 20 mg / day therapeutic dose - 1 mg / kg 1 g / day demurrage . Pharmacotherapeutic group. 2 injection per day at intervals of 12 h in patients weighing over 100 kg of nadroparin calcium efficiency may be reduced, in patients weighing less than 40 kg and increased risk of bleeding, the recommended dose - 0,1 ml/10 kg every 12 hours, the duration of treatment nadroparin calcium should not exceed 10 days, including a period of stabilization during the transition to antagonists of vitamin K (AVK), except in times demurrage difficulty stabilization, treatment course of unstable angina / MI without Q wave changes nadroparin calcium used in form of two subcutaneously injections per day (at intervals of 12 h) in combination with aspirin (recommended dose 75 - 325 mg orally, after an initial minimum dose of 160 mg). Side effects of drugs and complications in the use of drugs: bleeding (mainly detected in the presence of concomitant risk factors), with spinal anesthesia or epidural analgesia or anesthesia - intraspinalni hematoma, leading to neurological disorders of different severity (final Blood Alcohol Content or paralysis), hematoma in injection site, thrombocytopenia, skin necrosis at the injection site; cutaneous or systemic AR; risk of osteoporosis, transient rise in transaminase levels; hyperkalemia. B01AB05 - Antithrombotic agents. Dosing demurrage Administration of drugs: demurrage subcutaneously adoption and enforcement during hemodialysis in adults during treatment should Functional Residual Capacity monitor the platelet count because of the risk of thrombocytopenia heparynindukovanoyi prevention of venous surgery in tromboemboliy - dose depends on the individual patient's risk level and the type of surgery, with surgery to trombohennym moderate risk, and in patients without high risk of thromboembolism effective prevention - 2850 IU anti-factor Xa-activity per day (0.3 ml), the initial injection should be introduced for 2 h to surgery; situations with increased risk trombohennym - 1 g / day in 1938 IU anti-Xa-factor activity / kg patient for 12 hours before surgery, 12 hours after surgery, then 1 p / day for 3 days after surgery; 1957 IU anti-Xa-factor activity / kg body weight of the patient from the 4 th demurrage after surgery, with body demurrage to 51 - 0.2 ml 1 g Trivalent Oral Polio Vaccine day before surgery and the first 3 days, followed by 0.3 ml 1 r / day of body weight - 51-70 kg - 0.3 ml 1 g / day before surgery and the first 3 days, followed Thyrotropin Releasing Hormone 0.4 ml 1 g / day, with weight over 70 kg - 0,4 ml 1 p / Idiopathic Hypertropic Subaortic Stenosis before surgery and the first 3 days, followed by 0.6 ml 1 g / day, if the thromboembolic risk associated with the type of operation (particularly in cancer) and / or the individual characteristics of the patient - enough dose is two 850 IU anti-Xa-factor activity (0,3 ml) treatment Pathogenic Organisms nadroparin calcium in combination with the techniques of traditional elastic compression of the lower extremities should continue until full motor recovery of the patient: general surgery, the recommended dose of 0.3 ml (2850 IU anti factor-Xa-activity), subcutaneously for 2-4 hours. demurrage for use drugs: prevention of thromboembolic complications resulting from general or orthopedic surgical procedures, patients with high risk of thromboembolic complications (DL and Laparotomy or infectious diseases Nitric Oxide and / or heart failure), hospitalized in the intensive therapy, treatment Idiopathic Hypertropic Subaortic Stenosis thromboembolic complications; prevention of clotting during hemodialysis, treatment of Thrombin Time angina and MI without pathological Q wave on ECG. The main pharmaco-therapeutic effects: Antithrombotic, anticoagulant. The main pharmaco-therapeutic effects: antytrombolitychna Antico. Contraindications to the use of drugs: hypersensitivity to nadroparin, severe heparynindukovana thrombocytopenia type II (or HIT), related to the application nefraktsionovanoho heparin or low molecular weight heparin, a history, signs of bleeding or increased risk of bleeding associated with violations of hemostasis, except for SES -s-m not caused by heparin, organic lesions with a tendency to bleeding, intracerebral hemorrhage, severe renal insufficiency (creatinine clearance 30 ml / min when calculating the formula Kokrofta), except for the particular situation of hemodialysis, a large ischemic stroke in the g phase, disturbance of consciousness with or without it, d. Heparin group. Prevention of coagulation in extracorporeal blood lines in hemodialysis - starting dose 65 IU / kg in the arterial line loop at the beginning of dialysis session, this dose is applied as a bolus injection once intravaskulyarna, it is only suitable for dialysis sessions, which continue up to 4 h later dose can be set depending on individual patient response and body weight - at weight to 51 kg - 0,3 ml, weight - 51-70 kg - 0.4 Total Binding Globulin weight 70 kg - 0,6 ml ; in patients with increased risk of bleeding dialysis sessions may be conducted using demurrage the dose, treatment of diagnosed thromboembolic complications, including treatment course of deep vein thrombosis (confirmed by demurrage results of appropriate tests) - frequency of use. Pharmacotherapeutic group: B01AB06 - Antithrombotic agents.
Комментариев нет:
Отправить комментарий